Phaseline

Companies › Ribocure Pharmaceuticals

Ribocure Pharmaceuticals: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 2; Cardiovascular, Infectious disease; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
RBD5044–Phase 2DyslipidemiasMay 2027
RBD1016
Unclear - no mechanism stated
–Phase 2Chronic Hepatitis DAug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06797401RBD5044Phase 2DyslipidemiasCardiovascularMay 2027
NCT06649266RBD1016Phase 2Chronic Hepatitis DInfectious diseaseAug 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

TaiMed Biologics Suzhou HepaThera Biotech Hyundai Bioscience Cardurion Pharmaceuticals Research Institute of Geroprotective Technologies

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.